Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomised phase 2 trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor-prognosis germ cell tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604).
Huddart RA, Gabe R, Cafferty FH, Pollock P, White JD, Shamash J, Cullen MH, Stenning SP; TE23 Trial Management Group and Collaborators; National Cancer Research Institute Testis Cancer Clinical Studies Group. Huddart RA, et al. Among authors: cafferty fh. Eur Urol. 2015 Mar;67(3):534-43. doi: 10.1016/j.eururo.2014.06.034. Epub 2014 Jul 4. Eur Urol. 2015. PMID: 25001888 Free PMC article. Clinical Trial.
Re: Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. M. R. Smith, R. A. Morton, K. G. Barnette, P. R. Sieber, S. B. Malkowicz, D. Rodriguez, M. L. Hancock and M. S. Steiner. J Urol 2010;184:1316-1321.
Langley RE, Cafferty FH, Pollock PA, Price P, Abel PD. Langley RE, et al. Among authors: cafferty fh. J Urol. 2011 Jun;185(6):2430-1; author reply 2431-2. doi: 10.1016/j.juro.2011.02.036. Epub 2011 Apr 22. J Urol. 2011. PMID: 21513954 No abstract available.
UK management practices in stage I seminoma and the Medical Research Council Trial of Imaging and Schedule in Seminoma Testis managed with surveillance.
Cafferty FH, Gabe R, Huddart RA, Rustin G, Williams MP, Stenning SP, Bara A, Bathia R, Freeman SC, Alder L, Joffe JK. Cafferty FH, et al. Clin Oncol (R Coll Radiol). 2012 Feb;24(1):25-9. doi: 10.1016/j.clon.2011.09.005. Epub 2011 Sep 28. Clin Oncol (R Coll Radiol). 2012. PMID: 21955594 No abstract available.
Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09).
Langley RE, Cafferty FH, Alhasso AA, Rosen SD, Sundaram SK, Freeman SC, Pollock P, Jinks RC, Godsland IF, Kockelbergh R, Clarke NW, Kynaston HG, Parmar MK, Abel PD. Langley RE, et al. Among authors: cafferty fh. Lancet Oncol. 2013 Apr;14(4):306-16. doi: 10.1016/S1470-2045(13)70025-1. Epub 2013 Mar 4. Lancet Oncol. 2013. PMID: 23465742 Free PMC article. Clinical Trial.
A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol.
Langley RE, Kynaston HG, Alhasso AA, Duong T, Paez EM, Jovic G, Scrase CD, Robertson A, Cafferty F, Welland A, Carpenter R, Honeyfield L, Abel RL, Stone M, Parmar MK, Abel PD. Langley RE, et al. Eur Urol. 2016 Jun;69(6):1016-25. doi: 10.1016/j.eururo.2015.11.030. Epub 2015 Dec 17. Eur Urol. 2016. PMID: 26707868 Free PMC article. Clinical Trial.
Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma: A Randomized Phase 2 Clinical Trial.
Smyth EC, Rowley S, Cafferty FH, Allum W, Grabsch HI, Stenning S, Wotherspoon A, Alderson D, Crosby T, Mansoor W, Waters JS, Neville-Webbe H, Darby S, Dent J, Seymour M, Thompson J, Sothi S, Blazeby J, Langley RE, Cunningham D. Smyth EC, et al. Among authors: cafferty fh. JAMA Oncol. 2019 Aug 1;5(8):1181-1187. doi: 10.1001/jamaoncol.2019.1179. JAMA Oncol. 2019. PMID: 31219517 Free PMC article.
Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial.
Joharatnam-Hogan N, Cafferty F, Hubner R, Swinson D, Sothi S, Gupta K, Falk S, Patel K, Warner N, Kunene V, Rowley S, Khabra K, Underwood T, Jankowski J, Bridgewater J, Crossley A, Henson V, Berkman L, Gilbert D, Kynaston H, Ring A, Cameron D, Din F, Graham J, Iveson T, Adams R, Thomas A, Wilson R, Pramesh CS, Langley R; Add-Aspirin Trial Management Group. Joharatnam-Hogan N, et al. Lancet Gastroenterol Hepatol. 2019 Nov;4(11):854-862. doi: 10.1016/S2468-1253(19)30289-4. Epub 2019 Aug 30. Lancet Gastroenterol Hepatol. 2019. PMID: 31477558 Free article. Clinical Trial.
Long-term outcomes with intensive induction chemotherapy (carboplatin, bleomycin, vincristine and cisplatin/bleomycin, etoposide and cisplatin) and standard bleomycin, etoposide and cisplatin in poor prognosis germ cell tumours: A randomised phase II trial (ISRCTN53643604).
Cafferty FH, White JD, Shamash J, Hennig I, Stenning SP, Huddart RA; TE23 Trial Management Group and Collaborators. Cafferty FH, et al. Eur J Cancer. 2020 Mar;127:139-149. doi: 10.1016/j.ejca.2019.12.028. Epub 2020 Jan 31. Eur J Cancer. 2020. PMID: 32007714 Free PMC article. Clinical Trial.
61 results